Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$157.46 1.35 (0.86%)
2/9/2010 4:00 PM

Alcon, Inc. (ACL)

CAPS Rating:
****

The Company develops, manufactures and markets pharmaceuticals, surgical equipment and devices and consumer eye care products to treat diseases and disorders of the eye.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ACL

Add Stock to Watchlist

What the Community Thinks

Total Members

363 Outperforms
19 Underperforms
 

All-Stars

130 Outperforms
9 Underperforms
 

Wall Street

6 Outperforms
1 Underperforms
 

Members bullish on ACL are also bullish on:

Members bearish on ACL are also bearish on:

Ticker Tags

International Stock (684), Switzerland (8), Healthcare Equipment and Supplies (176), Defensive (1457), Healthcare (711), Supplies (52), Growth (1902), Blue Chip (106), Large Cap (413)
Suggest a tag

Alcon, Inc. At A Glance

Current Price: $157.46
Last Trade Time: 2/9/2010 4:00 PM
Open: $156.42
Previous Close: $156.11
Daily Range: $156.00 - $157.95
52-Week Range: $76.03 - $166.71
Volume: 490,315
Market Cap: $47.03B
P/E Ratio: 23.62
Compare Our Special Broker Offers!

Stock Trends

ACL VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for ACL

More Headlines...

Top Bull Pitch

Recs

1

Alcon, Inc. (ACL)

Avatar wooderino (96.95) Submitted: 10/27/09 12:35 PM

Showed up on a screen for solid 5 year growth with low debt, cash on hand and still at attractive P/E ratios.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 58 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (ACL)

Avatar ripestocks (< 20) Submitted: 1/24/10 9:57 PM : Outperform Start Price: $156.10 ACL Score: 3.58

* Alcon's fundamentals are fantastic. Solid growth in all key areas over the past 10 years (ROI, Equity Growth, EPS Growth, and Sales Growth).
* Alcon's 2.3% dividend is not too shabby either
* I really see 2 things going on for Alcon in the short term:
- First, Alcon has experienced a decent downward momentum as of late that seems to have bottomed out. I am expecting this trend to reverse and catch some upward momentum shortly.
- Here is the real reason why I see upward gains with ACL: This month Novartis paid Nestle $180 a share to gain a controlling stake in Alcon but they only offered 2.8 Novartis shares for each Alcon share (which is an offer of about 150-ish dollars). Alcon's independent directors made it clear this month that his offer is disgusting and a slap in the face to minority shareholder. However, my expectation is that Novartis will raise their offer to make this problem go away.

See my full analysis at
http://www.ripe-stocks.com/RipeStocks/stock/ViewStockEntry.action?stockEntryId=8

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACL)

Avatar colonel79 (35.17) Submitted: 1/22/10 6:36 PM : Underperform Start Price: $156.10 ACL Score: -3.58

Nice company, but a bit pricey for the estimated future earnings. Think this could pull back in a bit and be a buy. Chart looks like it is selling off a bit. Amazing ROE and ROA. Good dividend as well.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACL)

Avatar btthus (93.14) Submitted: 12/26/09 3:07 AM : Outperform Start Price: $160.81 ACL Score: 2.95

pe, scottrade

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACL)

Avatar airenInDebt (64.37) Submitted: 12/03/09 4:26 PM : Outperform Start Price: $160.06 ACL Score: 2.51

Alcon's contact solutions and eye drops kick myopic ass!
Seriously, I've had contacts for about 25 years and have used all sorts of products. While their contact solution is the most expensive, it's hands down the best. Even if the stock price seems high, the company makes the best product and has no competition. I'm buyin!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACL)

Avatar Nostradamuss (23.64) Submitted: 10/27/09 7:15 PM : Outperform Start Price: $147.99 ACL Score: 5.39

Nice company

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 58 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackSunTrustRH 87.33 06/10/09 Outperform NS $114.60+37.40%+13.47%+23.93
TrackFTNEquityCa 65.55 01/21/09 Outperform NS $80.01+96.79%+33.17%+63.63
TrackCollinsStew 68.03 12/17/08 Outperform NS $80.09+96.60%+21.09%+75.51
TrackJimCramer < 20 08/25/08 Underperform 3W $164.28-4.15%-12.90%-8.75
TrackJefferies 82.08 06/14/07 Outperform NS $127.75+23.26%-25.46%+48.71
TrackBMOCapital 91.22 04/30/07 Outperform NS $127.54+23.46%-24.10%+47.56
TrackBofASec 94.61 04/05/07 Outperform NS $125.12+25.84%-21.10%+46.95

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 296ms